HospiMedica

Download Mobile App
Recent News AI Critical Care Surgical Techniques Patient Care Health IT Point of Care Business Focus

Wearable Device Monitors Vital Signs Continuously

By HospiMedica International staff writers
Posted on 27 Oct 2015
Image: The Zensor system (Photo courtesy of Intelesens).
Image: The Zensor system (Photo courtesy of Intelesens).
A novel wearable vital signs monitor facilitates real time monitoring of electrocardiogram (ECG) signals, heart rate, respiration rate, and motion.

The Zensor is a miniaturized clip on device that is attached to a disposable adhesive electrode array that monitors a range of vital signs data, transmitting information wirelessly to a remote server for a period of up to 168 hours (7 days) in a home or remote setting. During the week long monitoring session, the device is also capable of recording full interpretive ECG data for download and analysis by a trained healthcare professional. The system provides full configurability of the duration and frequency of monitored data, including the length of each recorded event.

Features of the system include 3-lead ECG full disclosure and cardiac event monitoring; symptomatic and asymptomatic arrhythmia event detection using on-device algorithms; monitoring of heart rate, respiration, and motion; and a rechargeable battery, replaceable in situ, when needed for extended periods of continuous use. The highly miniaturized, reusable, compact and lightweight body-worn wireless sensor is non-irritant, and is easy-to-apply using the long-life patch electrodes.

Transmission of detected arrhythmias and rate limit breaches is over standard Wi-Fi or mobile hotspot to the zensoronline website, with normal ranges and pre and post event data reporting configurable by the clinician. Data can also be downloaded via USB to zensor+ software. The Zensor vital signs monitor is a product of Intelesens (Belfast, United Kingdom), and has been approved by the US Food and Drug Administration (FDA).

“FDA clearance gives Intelesens and customers confidence in Zensor’s quality, robustness, and clinical efficacy,” said Stephen Henderson, commercial manager of Intelesens. “It brings a step closer the promise of preventative, predictive and protective technology, enabling clinicians proactively to help safeguard the quality of the life patients have yet to live.”

Related Links:

Intelesens
Zensoronline


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Ureteral Dilatation Balloon
Dornier Equinox
Neonatal Ventilator Simulation Device
Disposable Infant Test Lung

Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more